Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

INTRODUCTION: OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA) was a randomized, double-blind comparison of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch in patients with mild-to-moderate Alzheimer’s disease who declined despite open-label treatment with 9.5 mg/24 ...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Alzheimers Res Ther
Egile Nagusiak: Molinuevo, José L, Frölich, Lutz, Grossberg, George T, Galvin, James E, Cummings, Jeffrey L, Krahnke, Tillmann, Strohmaier, Christine
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4353453/
https://ncbi.nlm.nih.gov/pubmed/25755685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-014-0088-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak